Where Does Tenax Therapeutics Inc Stock Fall in the Biotechnology Field After It Is Lower By -22.06 percent This Week - InvestorsObserver

TENX Stock  USD 6.28  0.06  0.96%   
Slightly above 55% of Tenax Therapeutics' investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Tenax Therapeutics suggests that some traders are interested. Tenax Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Tenax Therapeutics' earnings reports, geopolitical events, and overall market trends.
  
Where Does Tenax Therapeutics Inc Stock Fall in the Biotechnology Field After It Is Lower By -22.06 percent This Week InvestorsObserver

Read at news.google.com
Google News at Macroaxis
  

Tenax Therapeutics Fundamental Analysis

We analyze Tenax Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tenax Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tenax Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Shares Outstanding

Shares Outstanding Comparative Analysis

Tenax Therapeutics is currently under evaluation in shares outstanding category among its peers. Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.

Tenax Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Tenax Therapeutics stock to make a market-neutral strategy. Peer analysis of Tenax Therapeutics could also be used in its relative valuation, which is a method of valuing Tenax Therapeutics by comparing valuation metrics with similar companies.

Peers

Tenax Therapeutics Related Equities

VRAXVirax Biolabs   27.98   
0%
100.0%
SONNSonnet Biotherapeutics   8.57   
0%
30.0%
NRBONeurobo Pharmaceuticals   1.42   
0%
5.0%
ZVSAZyVersa Therapeutics   0.81   
0%
2.0%
DRMADermata Therapeutics   1.40   
5.0%
0%
REVBRevelation Biosciences   1.54   
5.0%
0%
UNCYUnicycive Therapeutics   2.56   
9.0%
0%
WINTWindtree Therapeutics   3.13   
11.0%
0%
ALLRAllarity Therapeutics   3.77   
13.0%
0%
QNRXQuoin Pharmaceuticals   4.29   
15.0%
0%
ADTXAditxt   4.76   
17.0%
0%
ENSCEnsysce Biosciences   5.79   
20.0%
0%

Additional Tools for Tenax Stock Analysis

When running Tenax Therapeutics' price analysis, check to measure Tenax Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tenax Therapeutics is operating at the current time. Most of Tenax Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tenax Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tenax Therapeutics' price. Additionally, you may evaluate how the addition of Tenax Therapeutics to your portfolios can decrease your overall portfolio volatility.